<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04589143</url>
  </required_header>
  <id_info>
    <org_study_id>Second Xiangya hospital</org_study_id>
    <nct_id>NCT04589143</nct_id>
  </id_info>
  <brief_title>Agomelatine Augmentation Added to SSRIs or SNRIs for Depression</brief_title>
  <official_title>Agomelatine Added to SSRIs or SNRIs for Early-nonresponsive Patients With Major Depressive Disorder: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the efficacy and safety of agomelatine augmentation&#xD;
      antidepressant therapy in patients with major depressive disorder with inadequate response&#xD;
      during early stage of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>at baseline and in 2, 4 and 8 week</time_frame>
    <description>The ratio of patients who achieved percentage improvement of HAMD17 score ≥50%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission rate</measure>
    <time_frame>at baseline and in 2, 4 and 8 week</time_frame>
    <description>The ratio of patients who achieved HAMD17 score ≤ 7 points</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>MDD</condition>
  <arm_group>
    <arm_group_label>Experience group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group,participants take agomelatine at a dose of 25-50 mg/d for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Contral group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this group,participants take a placebo at a dose of 25-50 mg/d for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Agomelatine</intervention_name>
    <description>Oral tablets of agomelatine at a dose of 25-50 mg/d for 8 weeks</description>
    <arm_group_label>Experience group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Oral tablets of placebos at a dose of 25-50 mg/d for 8 weeks</description>
    <arm_group_label>Contral group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -1.Aged 18-60 years old; 2.Meeting the Diagnostic and Statistical Manual of Mental&#xD;
        Disorders, Fourth Edition-Text Revision (DSM-IV-TR) criteria for a current major depressive&#xD;
        episode; 3.Inadequate response to antidepressants with at least 2-weeks treatment duration&#xD;
        and under a standard dose. Inadequate response is defined by a &lt; 20% in the percentage&#xD;
        change of HAMD-17 score or according to patients' self-report in antidepressant treatment&#xD;
        questionnaire. Standard dose is defined as follows: sertraline: &gt;50mg; fluoxetine: &gt;20 mg;&#xD;
        citalopram: &gt;20 mg; escitalopram: &gt;10mg; venlafaxine: &gt;150 mg; duloxetine: &gt;60 mg; 4.Score&#xD;
        of Clinical Global Impression-Severity (CGI-S) ≥4; 5.Educational level of junior high&#xD;
        school and above, having the ability to give informed consent and complete cognitive tests.&#xD;
&#xD;
        6.The primary providers agreeing and patients willing to maintain current antidepressants&#xD;
        with the adjunctive treatment of agomelatine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Current or history of a systematic medical condition (especially rheumatic-immune&#xD;
             systemic diseases, endocrine and metabolism diseases, and neurologic system diseases),&#xD;
             brain injury or loss of consciousness for more than 5 minutes; 2.Significant current&#xD;
             suicidal ideation or suicidal attempt; 3.Meeting the criteria of substance use&#xD;
             disorder according to DSM-5 during the past 6 months; 4.History of adjunctive&#xD;
             treatment with antidepressants and/or antipsychotics (allowing a combination of small&#xD;
             doses of benzodiazepines); 5.Having used anticoagulants (heparin, warfarin, etc.),&#xD;
             glucocorticoids or medications for thyroid diseases in the past 3 months; 6.Abnormal&#xD;
             urine toxicology or thyroid screening results; 7.History of seizures or family history&#xD;
             of epilepsy; 8.History of antidepressant treatment other than medication within the&#xD;
             past six months (i.e. ECT, rTMS, psychotherapy); 9.Pregnant or breast breeding women;&#xD;
             10.Color-blindness 11.Transaminase (ALT and AST) showed in liver function tests 2&#xD;
             times above the upper limit of the normal range; 12.Electrocardiogram examination of&#xD;
             QTc ≥ 430 ms in male, QTc ≥ 450 ms in female.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lingjiang Li, MD Ph.D</last_name>
    <phone>+86 13807314575</phone>
    <email>LLJ2920@csu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mental Health Institute &amp; Faculty of Psychiatry of The Second Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lingjiang Li, MD Ph.D</last_name>
      <phone>+86 13807314575</phone>
      <email>LLJ2920@csu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Lingjiang Li</investigator_full_name>
    <investigator_title>President of Chinese Psychiatry Society of Chinese Medical Association</investigator_title>
  </responsible_party>
  <keyword>adjunctive agomelatine</keyword>
  <keyword>antidepressant therapy</keyword>
  <keyword>major depressive disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>S 20098</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

